Chronic Hepatitis B in Which HBs Antigen Seroclearance Was Induced by Pegpegylated-interferonα-2a after Hepatocellular Carcinoma Treatment with Nucleos(t)ide Analogues: A Five-year Follow-up.

IF 1 4区医学 Q3 MEDICINE, GENERAL & INTERNAL

Internal Medicine Pub Date : 2025-01-15 Epub Date: 2024-05-30 DOI:10.2169/internalmedicine.3643-24

Shima Mimura, Masafumi Ono, Koji Fujita, Kei Takuma, Mai Nakahara, Kyoko Oura, Tomoko Tadokoro, Joji Tani, Asahiro Morishita, Seiko Kagawa, Keiichi Okano, Takashi Himoto, Tsutomu Masaki

引用次数: 0

Abstract

We herein report a 40-year-old Japanese man with chronic hepatitis B genotype C (viral load 6.7 Log copies/mL) who developed hepatocellular carcinoma (HCC) despite achieving undetectable hepatitis B virus (HBV)-DNA levels with nucleos(t)ide analog (NA) treatment (entecavir). Notably, his hepatitis B surface antigen (HBsAg) level remained elevated at 388.4 IU/mL. Given the continued risk of carcinogenesis associated with HBsAg positivity, we initiated pegylated interferon (PEG-IFN) therapy one month after HCC surgery. Following three periods of PEG-IFN treatment, HBsAg seroclearance (HBsAg-negative state) was achieved.

查看原文本刊更多论文

用核苷酸类似物治疗肝细胞癌后，聚乙二醇化干扰素α-2a 诱导 HBs 抗原血清清除的慢性乙型肝炎病例：五年随访。

我们在此报告了一名 40 岁的日本男子，他患有慢性乙型肝炎基因型 C（病毒载量为 6.7 LC/mL），在接受核苷（t）ide 类似物（NA）治疗（恩替卡韦）后，他的乙型肝炎病毒（HBV）DNA 水平检测不到，但还是患上了肝细胞癌（HCC）。值得注意的是，他的乙型肝炎表面抗原（HBsAg）水平仍然高达 388.4 IU/mL。鉴于 HBsAg 阳性仍有致癌风险，我们在 HCC 手术后一个月开始了聚乙二醇干扰素（PEG-IFN）治疗。经过三个疗程的 PEG-IFN 治疗后，HBsAg 血清清除（HBsAg 阴性）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Internal Medicine 医学-医学：内科

CiteScore

1.90

自引率

8.30%

发文量

审稿时长

2.2 months

期刊介绍： Internal Medicine is an open-access online only journal published monthly by the Japanese Society of Internal Medicine. Articles must be prepared in accordance with "The Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see Annals of Internal Medicine 108: 258-265, 1988), must be contributed solely to the Internal Medicine, and become the property of the Japanese Society of Internal Medicine. Statements contained therein are the responsibility of the author(s). The Society reserves copyright and renewal on all published material and such material may not be reproduced in any form without the written permission of the Society.